Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
GT Biopharma, Inc. (GTBP) had Consolidated Net Income/Loss of $-1.43M for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
-- |
|
$-1.52M |
|
-- |
|
-- |
|
$1.51M |
|
$-1.51M |
|
$0.08M |
|
$-1.43M |
|
$-1.43M |
|
$-1.43M |
|
$-1.43M |
|
|
Consolidated Net Income/Loss |
$-1.43M |
$-1.43M |
|
$-1.51M |
|
$-1.51M |
|
2.77M |
|
2.77M |
|
$-0.55 |
|
$-0.55 |
|
| Balance Sheet Financials | |
$6.36M |
|
-- |
|
$0.76M |
|
$7.12M |
|
$2.31M |
|
-- |
|
$1.96M |
|
$4.26M |
|
$2.86M |
|
$2.86M |
|
$2.86M |
|
3.27M |
|
| Cash Flow Statement Financials | |
$-5.22M |
|
-- |
|
$6.49M |
|
$4.04M |
|
$5.32M |
|
$1.28M |
|
$0.01M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.76 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-5.22M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-50.11% |
|
-50.09% |
|
-20.12% |
|
-50.09% |
|
$0.87 |
|
$-1.88 |
|
$-1.88 |
|